Systems Toxicology: Real World Applications and Opportunities

Chemical Research in Toxicology

Volumn 30, Issue 4, 2017, Pages 870-882

  Hartung, Thomas ^a,b   FitzGerald, Rex E ^c   Jennings, Paul ^d   Mirams, Gary R ^e   Peitsch, Manuel C ^f   Rostami Hodjegan, Amin ^g,h   Shah, Imran ⁱ   Wilks, Martin F ^c   Sturla, Shana J ^j  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^f PHILIP MORRIS PRODUCTS S A   (Switzerland)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h CERTARA UK LIMITED   (United Kingdom)

ⁱ National Center for Computational Toxicology   (United States)

^j ETH ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTOXICITY; HIGH THROUGHPUT SEQUENCING; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; PHARMACOKINETICS; PHENOTYPE; REVIEW; TOXICOLOGY; DRUG EFFECTS; HALF LIFE TIME; HEART; HIGH THROUGHPUT SCREENING; KIDNEY; LIVER; METABOLOMICS; PROTEOMICS; THEORETICAL MODEL;

XENOBIOTIC AGENT;

HALF-LIFE; HEART; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KIDNEY; LIVER; METABOLOMICS; MODELS, THEORETICAL; PROTEOMICS; XENOBIOTICS;

EID: 85018472124     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/acs.chemrestox.7b00003     Document Type: Review

References (138)

1. Sturla, S. J., Boobis, A. R., FitzGerald, R. E., Hoeng, J., Kavlock, R. J., Schirmer, K., Whelan, M., Wilks, M. F., and Peitsch, M. C. ( 2014 ) Systems toxicology: from basic research to risk assessment Chem. Res. Toxicol. 27, 314-329 10.1021/tx400410s
2. Ferrario, D. and Hartung, T. ( 2014 ) Glossary of reference terms for alternative test methods and their validation ALTEX 31, 319-335 10.14573/altex.140331
3. Duffus, J. H., Nordberg, M., and Templeton, D. M. ( 2007 ) Glossary of terms used in toxicology, 2nd edition Pure Appl. Chem. 79, 1153-1344 10.1351/pac200779071153
4. Smirnova, L., Harris, G., Leist, M., and Hartung, T. ( 2015 ) Cellular Resilience ALTEX 32, 247-260 10.14573/altex.1509271
5. Systems Toxicology (2016) https://systox.ch (last accessed 21 Mar, 2017).
6. Ankley, G., Escher, B., Hartung, T., and Shah, I. ( 2016 ) Pathway-based approaches for environmental monitoring and risk assessment Chem. Res. Toxicol. 29, 1789-1790 10.1021/acs.chemrestox.6b00321
7. National Research Council/National Academy of Sciences ( 2007 ) Toxicity Testing in the 21st Century: A Vision and a Strategy. The National Academies Press, Washington, DC. DOI: 10.17226/11970.
8. Hartung, T. and McBride, M. ( 2011 ) Food for thought··· on mapping the human toxome ALTEX 28, 83-93 10.14573/altex.2011.2.083
9. van Vliet, E., Danesian, M., Beilmann, M., Davies, A., Fava, E., Fleck, R., Julé, Y., Kansy, M., Kustermann, S., Macko, P., Mundy, W., Roth, A., Shah, I., Uteng, M., van de Water, B., Hartung, T., and Leist, M. ( 2014 ) Current approaches and future role of high content imaging in safety sciences and drug discovery ALTEX 31, 479-493
10. Judson, R. S., Mortensen, H. M., Shah, I., Knudsen, T. B., and Elloumi, F. ( 2012 ) Using pathway modules as targets for assay development in xenobiotic screening Mol. BioSyst. 8, 531-542 10.1039/C1MB05303E
11. Kleensang, A., Maertens, A., Rosenberg, M., Fitzpatrick, S., Lamb, J., Auerbach, S., Brennan, R., Crofton, K. M., Gordon, B., Fornace, A. J., Jr., Gaido, K., Gerhold, D., Haw, R., Henney, A., Ma’ayan, A., McBride, M., Monti, S., Ochs, M. F., Pandey, A., Sharan, R., Stierum, R., Tugendreich, S., Willett, C., Wittwehr, C., Xia, J., Patton, G. W., Arvidson, K., Bouhifd, M., Hogberg, H. T., Luechtefeld, T., Smirnova, L., Zhao, L., Adeleye, Y., Kanehisa, M., Carmichael, P., Andersen, M. E., and Hartung, T. ( 2014 ) Pathways of toxicity ALTEX 31, 53-61 10.14573/altex.1309261
12. Hartung, T., Stephens, M., and Hoffmann, S. ( 2013 ) Food for Thought...Mechanistic validation ALTEX 30, 119-130 10.14573/altex.2013.2.119
13. Boue, S., Fields, B., Hoeng, J., Park, J., Peitsch, M. C., Schlage, W. K., Talikka, M., Binenbaum, I., Bondarenko, V., Bulgakov, O. V., Cherkasova, V., Diaz-Diaz, N., Fedorova, L., Guryanova, S., Guzova, J., Igorevna Koroleva, G., Kozhemyakina, E., Kumar, R., Lavid, N., Lu, Q., Menon, S., Ouliel, Y., Peterson, S. C., Prokhorov, A., Sanders, E., Schrier, S., Schwaitzer Neta, G., Shvydchenko, I., Tallam, A., Villa-Fombuena, G., Wu, J., Yudkevich, I., and Zelikman, M. Enhancement of COPD biological networks using a web-based collaboration interface, DOI: 10.12688/f1000research.5984.2.
14. Hartung, T., van Vliet, E., Jaworska, J., Bonilla, L., Skinner, N., and Thomas, R. ( 2012 ) Systems toxicology ALTEX 29, 119-128 10.14573/altex.2012.2.119
15. Shah, I. and Wambaugh, J. ( 2010 ) Virtual tissues in toxicology J. Toxicol. Environ. Health, Part B 13 ( 2-4 ) 314-328 10.1080/10937404.2010.483948
16. Hutson, M. S., Leung, M. C., Baker, N. C., Spencer, R. M., and Knudsen, T. B. ( 2017 ) Computational Model of Secondary Palate Fusion and Disruption. Chem. Res. Toxicol., DOI: 10.1021/acs.chemrestox.6b00350.
17. 4 report ALTEX 31, 441-477 10.14573/altex1406111
18. Marx, U., Andersson, T. B., Bahinski, A., Beilmann, M., Beken, S., Cassee, F. R., Cirit, M., Daneshian, M., Fitzpatrick, S., Frey, O., Gaertner, C., Giese, C., Griffith, L., Hartung, T., Heringa, M. B., Hoeng, J., de Jong, W. H., Kojima, H., Kuehnl, J., Luch, A., Maschmeyer, I., Sakharov, D., Sips, A. J. A. M., Steger-Hartmann, T., Tagle, D. A., Tonevitsky, A., Tralau, T., Tsyb, S., van de Stolpe, A., Vandebriel, R., Vulto, P., Wang, J., Wiest, J., Rodenburg, M., and Roth, A. ( 2016 ) Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing using animals ALTEX 33, 272-321 10.14573/altex.1603161
19. Hartung, T. ( 2014 ) 3D-a new dimension of in vitro research Adv. Drug Delivery Rev. 69-70, vi 10.1016/j.addr.2014.04.003
20. OECD ( 2005 ) Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment, OECD Series on Testing and Assessment, Guidance Document 34, Environment Directorate, Organisation for Economic Cooperation and Development, Paris, France, ENV/JM/MONO(2005)14.
21. Baker, M. ( 2016 ) 1,500 scientists lift the lid on reproducibility Nature 533, 452-454 10.1038/533452a
22. Coecke, S., Balls, M., Bowe, G., Davis, J., Gstraunthaler, G., Hartung, T., Hay, R., Merten, O.-W., Price, A., Schechtman, L., Stacey, G., and Stokes, W. ( 2005 ) Guidance on Good Cell Culture Practice Altern. Lab. Anim. 33, 261-287
23. Pamies, D., Bal-Price, A., Simeonov, A., Tagle, D., Allen, D., Gerhold, D., Yin, D., Pistollato, F., Inutsuka, T., Sullivan, K., Stacey, G., Salem, H., Leist, M., Daneshian, M., Vemuri, M. C., McFarland, R., Coecke, S., Fitzpatrick, S. C., Lakshmipathy, U., Mack, A., Wang, W. B., Daiju, Y., Sekino, Y., Kanda, Y., Smirnova, L., and Hartung, T. ( 2016 ) Good Cell Culture Practice for stem cells and stem-cell-derived models ALTEX 34, 95-132 10.14573/altex.1607121
24. Pamies, D., Barreras, P., Block, K., Makri, G., Kumar, A., Wiersma, D., Smirnova, L., Zang, C., Bressler, J., Christian, K. M., Harris, G., Ming, G.-L., Kyro, K., Berlinicke, C., Song, H., Pardo, C. A., Hartung, T., and Hogberg, H. T. ( 2016 ) A human brain microphysiological system derived from iPSC to study central nervous system toxicity and disease. ALTEX, DOI: 10.14573/altex.1609122.
25. Leist, M., Efremova, L., and Karreman, C. ( 2010 ) Food for thought··· considerations and guidelines for basic test method descriptions in toxicology ALTEX 27, 309-317 10.14573/altex.2010.4.309
26. Pamies, D. and Hartung, T. ( 2017 ) 21st century cell culture for 21st century toxicology Chem. Res. Toxicol. 30, 43-52 10.1021/acs.chemrestox.6b00269
27. OECD ( 2016 ) http://www.oecd.org/env/ehs/testing/OECD_Draft_GIVIMP_in_Human_Safety_Assessment.pdf (last accessed 14 Dec 2016).
28. National Institute of Environmental Health Sciences ( 1997 ) Validation and Regulatory Acceptance of Toxicological Test Methods: A Report of the ad Hoc Interagency Coordinating Committee on the Validation of Alternative Methods, NIH Publication No. 97-3981, NIEHS, Research Triangle Park, NC.
29. Jennings, P. ( 2015 ) The future of in vitro toxicology Toxicol. In Vitro 29, 1217-1221 10.1016/j.tiv.2014.08.011
30. Hartung, T., Bremer, S., Casati, S., Coecke, S., Corvi, R., Fortaner, S., Gribaldo, L., Halder, M., Hoffmann, S., Roi, A. J., Prieto, P., Sabbioni, E., Scott, L., Worth, A., and Zuang, V. A. ( 2004 ) Modular approach to the ECVAM principles on test validity Altern. Lab. Anim. 32, 467-472
31. Leist, M., Hasiwa, M., Daneshian, M., and Hartung, T. ( 2012 ) Validation and quality control of replacement alternatives - current status and future challenges Toxicol. Res. 1, 8 10.1039/c2tx20011b
32. Pendse, S. N., Maertens, A., Rosenberg, M., Roy, D., Fasani, R., Vantangoli, M., Madnick, S., Boekelheide, K., Fornace, A., Odwin, S.-A., Yager, J., Hartung, T., Andersen, M. E., and McMullen, P. D. ( 2017 ) Information-dependent enrichment analysis reveals time-dependent transcriptional regulation of the estrogen pathway of toxicity Arch. Toxicol. 91, 1749 10.1007/s00204-016-1824-6
33. Bouhifd, M., Beger, R., Flynn, T., Guo, L., Harris, G., Hogberg, H. T., Kaddurah-Daouk, R., Kamp, H., Kleensang, A., Maertens, A., Odwin-DaCosta, S., Pamies, D., Robertson, D., Smirnova, L., Sun, J., Zhao, L., and Hartung, T. ( 2015 ) Quality assurance of metabolomics ALTEX 32, 319-326 10.14573/altex.1509161
34. Maertens, A., Bouhifd, M., Zhao, L., Odwin-DaCosta, S., Kleensang, A., Yager, J. D., and Hartung, T. ( 2017 ) Metabolomic network analysis of estrogen-stimulated MCF-7 cells: a comparison of over-representation analysis, quantitative enrichment analysis and pathway analysis versus metabolite network analysis Arch. Toxicol. 91, 217-230 10.1007/s00204-016-1695-x
35. Ramirez, T., Daneshian, M., Kamp, H., Bois, F. Y., Clench, M. R., Coen, M., Donley, B., Fischer, S. M., Ekman, D. R., Fabian, E., Guillou, C., Heuer, J., Hogberg, H. T., Jungnickel, H., Keun, H. C., Krennrich, G., Krupp, E., Luch, A., Noor, F., Peter, E., Riefke, B., Seymour, M., Skinner, N., Smirnova, L., Verheij, E., Wagner, S., Hartung, T., van Ravenzwaay, B., and Leist, M. ( 2013 ) Metabolomics in toxicology and preclinical research ALTEX 30, 209-225 10.14573/altex.2013.2.209
36. Bouhifd, M., Hartung, T., Hogberg, H. T., Kleensang, A., and Zhao, L. ( 2013 ) Review: toxicometabolomics J. Appl. Toxicol. 33, 1365-1383 10.1002/jat.2874
37. van Vliet, E. ( 2011 ) Current standing and future prospects for the technologies proposed to transform toxicity testing in the 21st century ALTEX 28, 17-44 10.14573/altex.2011.1.017
38. Maertens, A., Luechtefeld, T., Kleensang, A., and Hartung, T. ( 2015 ) MPTP’s pathway of toxicity indicates central role of transcription factor SP1 Arch. Toxicol. 89, 743-755 10.1007/s00204-015-1509-6
39. Pendse, S. N., Maertens, A., Rosenberg, M., Roy, D., Fasani, R., Vantangoli, M., Madnick, S., Boekelheide, K., Fornace, A., Odwin, S.-A., Yager, J., Hartung, T., Andersen, M. E., and McMullen, P. D. ( 2017 ) Information-dependent enrichment analysis reveals time-dependent transcriptional regulation of the estrogen pathway of toxicity Arch. Toxicol. 91, 1749 10.1007/s00204-016-1824-6
40. Bouhifd, M., Andersen, M. E., Baghdikian, C., Boekelheide, K., Crofton, K. M., Fornace, A. J., Jr., Kleensang, A., Li, H., Livi, C. B., Maertens, A., McMullen, P. D., Rosenberg, M., Thomas, R., Vantangoli, M., Yager, J. D., Zhao, L., and Hartung, T. ( 2015 ) The Human Toxome project ALTEX 32, 112-124 10.14573/altex.1502091
41. Ramirez, T., Daneshian, M., Kamp, H., Bois, F. Y., Clench, M. R., Coen, M., Donley, B., Fischer, S. M., Ekman, D. R., Fabian, E., Guillou, C., Heuer, J., Hogberg, H. T., Jungnickel, H., Keun, H. C., Krennrich, G., Krupp, E., Luch, A., Noor, F., Peter, E., Riefke, B., Seymour, M., Skinner, N., Smirnova, L., Verheij, E., Wagner, S., Hartung, T., van Ravenzwaay, B., and Leist, M. ( 2013 ) Metabolomics in toxicology and preclinical research ALTEX 30, 209-225 10.14573/altex.2013.2.209
42. Rappaport, S. M. and Smith, M. T. ( 2010 ) Environment and disease risks Science 330, 460-461 10.1126/science.1192603
43. Miller, G. W. and Jones, D. P. ( 2014 ) The nature of nurture: refining the definition of the exposome Toxicol. Sci. 137, 1-2 10.1093/toxsci/kft251
44. Escher, B. I., Hackermüller, J., Polte, T., Scholz, S., Aigner, A., Altenburger, R., Böhme, A., Bopp, S. K., Brack, W., Busch, W., Chadeau-Hyam, M., Covaci, A., Eisenträger, A., Galligan, J., Garcia-Reyero, N., Hartung, T., Hein, M., Herberth, G., Jahnke, A., Kleinjans, J., Kluever, N., Krauss, M., Lamoree, M., Lehmann, I., Luckenbach, T., Miller, G. W., Mueller, A., Phillips, D. H., Rappaport, S. M., Reemtsma, T., Rolle-Kampczyk, U., Schüürmann, G., Schwikowski, B., Tan, Y.-M., Trump, S., Walter-Rohde, S., and Wambaugh, J. F. ( 2017 ) From the exposome to mechanistic understanding of chemical-induced adverse effects Environ. Int. 99, 97-106 10.1016/j.envint.2016.11.029
45. Kavlock, R. and Dix, D. ( 2010 ) Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk J. Toxicol. Environ. Health, Part B 13, 197-217 10.1080/10937404.2010.483935
46. Judson, R., Kavlock, R., Martin, M., Reif, D., Houck, K., Knudsen, T., Richard, A., Tice, R., Whelan, M., Xia, M., Huang, R., Austin, C., Daston, G., Hartung, T., Fowle, J. R., III, Wooge, W., Tong, W., and Dix, D. ( 2013 ) Perspectives on validation of high-throughput pathway-based assays supporting the 21st century toxicity testing vision ALTEX 30, 51-66 10.14573/altex.2013.1.051
47. Hartung, T., Luechtefeld, T., Maertens, A., and Kleensang, A. ( 2013 ) Integrated testing strategies for safety assessments ALTEX 30, 3-18 10.14573/altex.2013.1.003
48. Rovida, C., Alépée, N., Api, A. M., Basketter, D. A., Bois, F. Y., Caloni, F., Corsini, E., Daneshian, M., Eskes, C., Ezendam, J., Fuchs, H., Hayden, P., Hegele-Hartung, C., Hoffmann, S., Hubesch, B., Jacobs, M. N., Jaworska, J., Kleensang, A., Kleinstreuer, N., Lalko, J., Landsiedel, R., Lebreux, F., Luechtefeld, T., Locatelli, M., Mehling, A., Natsch, A., Pitchford, J. W., Prater, D., Prieto, P., Schepky, A., Schuurmann, G., Smirnova, L., Toole, C., van Vliet, E., Weisensee, D., and Hartung, T. ( 2015 ) Integrated testing strategies (ITS) for safety assessment ALTEX 32, 171-181 10.14573/altex.1411011
49. Tollefsen, K. E., Scholz, S., Cronin, M. T., Edwards, S. W., de Knecht, J., Crofton, K., Garcia-Reyero, N., Hartung, T., Worth, A., and Patlewicz, G. ( 2014 ) Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA) Regul. Toxicol. Pharmacol. 70, 629-640 10.1016/j.yrtph.2014.09.009
50. Kleinstreuer, N. C., Yang, J., Berg, E. L., Knudsen, T. B., Richard, A. M., Martin, M. T., Reif, D. M., Judson, R. S., Polokoff, M., Dix, D. J., Kavlock, R. J., and Houck, K. A. ( 2014 ) Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms Nat. Biotechnol. 32, 583-591 10.1038/nbt.2914
51. Shah, I., Setzer, R. W., Jack, J., Houck, K. A., Judson, R. S., Knudsen, T. B., Liu, J., Martin, M. T., Reif, D. M., Richard, A. M., Thomas, R. S., Crofton, K. M., Dix, D. J., and Kavlock, R. J. ( 2016 ) Using ToxCast Data to Reconstruct Dynamic Cell State Trajectories and Estimate Toxicological Points of Departure Environ. Health Perspect. 124, 910-919 10.1289/ehp.1409029
52. Liu, J., Mansouri, K., Judson, R. S., Martin, M. T., Hong, H., Chen, M., Xu, X., Thomas, R. S., and Shah, I. ( 2015 ) Predicting Hepatotoxicity Using ToxCast in Vitro Bioactivity and Chemical Structure Chem. Res. Toxicol. 28, 738-751 10.1021/tx500501h
53. Van den Hof, W. F., Coonen, M. L., van Herwijnen, M., Brauers, K., Wodzig, W. K., van Delft, J. H., and Kleinjans, J. C. ( 2014 ) Classification of hepatotoxicants using HepG2 cells: A proof of principle study Chem. Res. Toxicol. 27, 433-442 10.1021/tx4004165
54. Garcia-Serna, R., Vidal, D., Remez, N., and Mestres, J. ( 2015 ) Large-scale predictive drug safety: from structural alerts to biological mechanisms Chem. Res. Toxicol. 28, 1875-1887 10.1021/acs.chemrestox.5b00260
55. Angrish, M. M., Madden, M. C., and Pleil, J. D. ( 2015 ) Probe molecule (PrM) approach in adverse outcome pathway (AOP) based high-throughput screening (HTS): in vivo discovery for developing in vitro target methods Chem. Res. Toxicol. 28, 551-559 10.1021/acs.chemrestox.5b00024
56. Gonzalez-Suarez, I., Sewer, A., Walker, P., Mathis, C., Ellis, S., Woodhouse, H., Guedj, E., Dulize, R., Marescotti, D., Acali, S., Martin, F., Ivanov, N. V., Hoeng, J., and Peitsch, M. C. ( 2014 ) Systems biology approach for evaluating the biological impact of environmental toxicants in vitro Chem. Res. Toxicol. 27, 367-376 10.1021/tx400405s
57. Mirams, G. R., Pathmanathan, P., Gray, R. A., Challenor, P., and Clayton, R. H. ( 2016 ) Uncertainty and variability in computational and mathematical models of cardiac physiology J. Physiol. 594, 6833-6847 10.1113/JP271671
58. Tsaioun, K., Blaauboer, B. J., and Hartung, T. ( 2016 ) Evidence-based absorption, distribution, metabolism, excretion and toxicity (ADMET) and the role of alternative methods ALTEX 33, 343-358 10.14573/altex.1610101
59. Hartung, T. ( 2009 ) Toxicology for the twenty-first century Nature 460, 208-212 10.1038/460208a
60. Boobis, A. R., Daston, G. P., Preston, R. J., and Olin, S. S. ( 2009 ) Application of key events analysis to chemical carcinogens and noncarcinogens Crit. Rev. Food Sci. Nutr. 49, 690-707 10.1080/10408390903098673
61. Meek, M. E., Boobis, A., Cote, I., Dellarco, V., Fotakis, G., Munn, S., Seed, J., and Vickers, C. ( 2014 ) New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis J. Appl. Toxicol. 34, 1-18 10.1002/jat.2949
62. Meek, M. E., Palermo, C. M., Bachman, A. N., North, C. M., and Jeffrey Lewis, R. ( 2014 ) Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence J. Appl. Toxicol. 34, 595-606 10.1002/jat.2984
63. Boobis, A. R., Cohen, S. M., Dellarco, V., McGregor, D., Meek, M. E., Vickers, C., Willcocks, D., and Farland, W. ( 2006 ) IPCS framework for analyzing the relevance of a cancer mode of action for humans Crit. Rev. Toxicol. 36, 781-792 10.1080/10408440600977677
64. Boobis, A. R., Doe, J. E., Heinrich-Hirsch, B., Meek, M. E., Munn, S., Ruchirawat, M., Schlatter, J., Seed, J., and Vickers, C. ( 2008 ) IPCS framework for analyzing the relevance of a noncancer mode of action for humans Crit. Rev. Toxicol. 38, 87-96 10.1080/10408440701749421
65. Villeneuve, D. L., Crump, D., Garcia-Reyero, N., Hecker, M., Hutchinson, T. H., LaLone, C. A., Landesmann, B., Lettieri, T., Munn, S., Nepelska, M., Ottinger, M. A., Vergauwen, L., and Whelan, M. ( 2014 ) Adverse outcome pathway development II: best practices Toxicol. Sci. 142, 321-330 10.1093/toxsci/kfu200
66. Jennings, P. ( 2013 ) Stress response pathways, toxicity pathways and adverse outcome pathways Arch. Toxicol. 87, 13-14 10.1007/s00204-012-0974-4
67. Yoon, M., Adeleye, Y., Clewell, R., Jennings, P., and Whelan, M. ( 2016 ) Moving beyond prioritization toward true in vitro safety assessment Appl. In Vitro Toxicol. 2, 67-73 10.1089/aivt.2016.29005.rtl
68. Hartung, T. ( 2017 ) Utility of the Adverse Outcome Pathway concept in drug development Expert Opin. Drug Metab. Toxicol. 13, 1-3 10.1080/17425255.2017.1246535
69. https://aopwiki.org/wiki/index.php/Main_Page (last accessed 21 Mar, 2017).
70. https://www.effectopedia.org (last accessed 21 Mar, 2017).
71. SCCS ( 2013 ) Addressing the New Challenges for Risk Assessment, Opinion adopted March 2013, European Union Scientific Committee on Health and Environmental Risks (SCHER), Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), Scientific Committee on Consumer Safety (SCCS). http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_131.pdf (accessed 26 Aug, 2016).
72. Daston, G., Knight, D. J., Schwarz, M., Gocht, T., Thomas, R. S., Mahony, C., and Whelan, M. ( 2015 ) SEURAT: Safety Evaluation Ultimately Replacing Animal Testing--recommendations for future research in the field of predictive toxicology Arch. Toxicol. 89, 15-23 10.1007/s00204-014-1421-5
73. Daneshian, M., Kamp, H., Hengstler, J., Leist, M., and van de Water, B. ( 2016 ) Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk Arch. Toxicol. 90, 1021-1024 10.1007/s00204-016-1698-7
74. http://www.eu-toxrisk.eu (last accessed 21 Mar, 2017).
75. Busquet, F. and Hartung, T. ( 2008 ) The need for strategic development of safety sciences ALTEX 34, 3-21 10.14573/altex.1701031
76. Allen, T. E. H., Goodman, J. M., Gutsell, S., and Russell, P. J. ( 2014 ) Defining molecular initiating events in the adverse outcome pathway framework for risk assessment Chem. Res. Toxicol. 27, 2100-2112 10.1021/tx500345j
77. Mellor, C. L., Steinmetz, F. P., and Cronin, M. T. D. ( 2016 ) Using molecular initiating events to develop a structural alert based screening workflow for nuclear receptor ligands associated with hepatic steatosis Chem. Res. Toxicol. 29, 203-212 10.1021/acs.chemrestox.5b00480
78. Mekenyan, O., Patlewicz, G., Kuseva, C., Popova, I., Mehmed, A., Kotov, S., Zhechev, T., Pavlov, T., Temelkov, S., and Roberts, D. W. ( 2014 ) A mechanistic approach to modeling respiratory sensitization Chem. Res. Toxicol. 27, 219-239 10.1021/tx400345b
79. Roberts, D. W. and Aptula, A. O. ( 2014 ) Electrophilic reactivity and skin sensitization potency of SNAr electrophiles Chem. Res. Toxicol. 27, 240-246 10.1021/tx400355n
80. Vinken, M. ( 2015 ) Adverse Outcome Pathways and drug-induced liver injury testing Chem. Res. Toxicol. 28, 1391-1397 10.1021/acs.chemrestox.5b00208
81. OECD ( 2013 ) Guidance Document on Developing and Assessing Adverse Outcome Pathways, OECD Environment Directorate, Joint Meeting of the Chemicals Committee and the Working Party on Chemicals, Pesticides and Biotechnology, Organisation for Economic Co-operation and Development, Series on Testing and Assessment No. 184, ENV/JM/MONO(2013)6, 17-Apr-2013. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2013)6&docLanguage=en.
82. OECD ( 2015 ) Report of the Workshop on a Framework for the Development and Use of Integrated Approaches to Testing and Assessment (17-19 Nov, 2014, Crystal City VA, USA), Organisation for Economic Co-operation and Development, Series on Testing and Assessment No. 215. ENV/JM/MONO(2015)22, 22-Jul-2015. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2015)22&docLanguage=En.
83. Benfenati, E., Berggren, E., Fritsche, E., Hartung, T., Slikker, W., Jr., Spielmann, H., Testai, E., Tice, R. R., Tiramani, M., and Villenave, R. ( 2016 ) Novel chemical hazard characterisation approaches EFSA J. 14, s0506 10.2903/j.efsa.2016.s0506
84. OECD ( 2015 ) Test Guideline 442C. In Chemico Skin Sensitisation. Direct Peptide Reactivity Assay (DPRA), OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects, published 05 February 2015. http://www.oecd-ilibrary.org/environment/test-no-442c-in-chemico-skin-sensitisation_9789264229709-en.
85. OECD ( 2015 ) Test Guideline 442D, In Vitro Skin Sensitisation, ARE-Nrf2 Luciferase Test Method, OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects, published 05 Feb, 2015. http://www.oecd-ilibrary.org/environment/test-no-442d-in-vitro-skin-sensitisation_9789264229822-en.
86. Natsch, A. and Emter, R. ( 2015 ) Reporter cell lines for skin sensitization testing Arch. Toxicol. 89, 1645-1468 10.1007/s00204-015-1555-0
87. Jaworska, J. S., Natsch, A., Ryan, C., Strickland, J., Ashikaga, T., and Miyazawa, M. ( 2015 ) Bayesian integrated testing strategy (ITS) for skin sensitization potency assessment: a decision support system for quantitative weight of evidence and adaptive testing strategy Arch. Toxicol. 89, 2355-2383 10.1007/s00204-015-1634-2
88. Strickland, J., Zang, Q., Kleinstreuer, N., Paris, M., Lehmann, D. M., Choksi, N., Matheson, J., Jacobs, A., Lowit, A., Allen, D., and Casey, W. ( 2016 ) Integrated decision strategies for skin sensitization hazard J. Appl. Toxicol. 36, 1150-1162 10.1002/jat.3281
89. Tollefsen, K. E., Scholz, S., Cronin, M. T., Edwards, S. W., de Knecht, J., Crofton, K., Garcia-Reyero, N., Hartung, T., Worth, A., and Patlewicz, G. ( 2014 ) Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA) Regul. Toxicol. Pharmacol. 70, 629-640 10.1016/j.yrtph.2014.09.009
90. Tralau, T., Oelgeschläger, M., Gürtler, R., Heinemeyer, G., Herzler, M., Höfer, T., Itter, H., Kuhl, T., Lange, N., Lorenz, N., Müller-Graf, C., Pabel, U., Pirow, R., Ritz, V., Schafft, H., Schneider, H., Schulz, T., Schumacher, D., Zellmer, S., Fleur-Böl, G., Greiner, M., Lahrssen-Wiederholt, M., Lampen, A., Luch, A., Schönfelder, G., Solecki, R., Wittkowski, R., and Hensel, A. ( 2015 ) Regulatory toxicology in the twenty-first century: challenges, perspectives and possible solutions Arch. Toxicol. 89, 823-850 10.1007/s00204-015-1510-0
91. Tralau, T. and Luch, A. ( 2015 ) Moving from rats to cellular omics in regulatory toxicology: great challenge toward sustainability or up-shit-creek without a paddle? Arch. Toxicol. 89, 819-821 10.1007/s00204-015-1511-z
92. Ankley, G., Escher, B., Hartung, T., and Shah, I. ( 2016 ) Pathway-based approaches for environmental monitoring and risk assessment Environ. Sci. Technol. 50, 10295-10296 10.1021/acs.est.6b04425
93. Rostami-Hodjegan, A. and Tucker, G. T. ( 2007 ) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data Nat. Rev. Drug Discovery 6, 140-148 10.1038/nrd2173
94. Gaohua, L., Wedagedera, J., Small, B. G., Almond, L., Romero, K., Hermann, D., Hanna, D., Jamei, M., and Gardner, I. ( 2015 ) Development of a multicompartment permeability-limited lung PBPK model and its application in predicting pulmonary pharmacokinetics of antituberculosis drugs CPT: Pharmacometrics Syst. Pharmacol. 4, 605-613 10.1002/psp4.12034
95. Neuhoff, S., Gaohua, L., Burt, H., Jamei, M., Li, L., Tucker, G. T., and Rostami-Hodjegan, A. ( 2013 ) Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM), in Transporters in Drug Development (Steffansen, B., and Sugiyama, Y., Eds.) pp 155-177, Springer, New York, DOI: 10.1007/978-1-4614-8229-1_7.
96. Neuhoff, S., Yeo, K. R., Barter, Z., Jamei, M., Turner, D. B., and Rostami-Hodjegan, A. ( 2013 ) Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux J. Pharm. Sci. 102, 3145-3160 10.1002/jps.23594
97. Jamei, M., Bajot, F., Neuhoff, S., Barter, Z., Yang, J., Rostami-Hodjegan, A., and Rowland-Yeo, K. ( 2014 ) A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine Clin. Pharmacokinet. 53, 73-87 10.1007/s40262-013-0097-y
98. Polak, S., Ghobadi, C., Mishra, H., Ahamadi, M., Patel, N., Jamei, M., and Rostami-Hodjegan, A. ( 2012 ) Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption J. Pharm. Sci. 101, 2584-2595 10.1002/jps.23155
99. Gaohua, L., Neuhoff, S., Johnson, T. N., Rostami-Hodjegan, A., and Jamei, M. ( 2016 ) Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro data Drug Metab. Pharmacokinet. 31, 224-233 10.1016/j.dmpk.2016.03.005
100. EMA ( 2016 ) Reflection Paper on Extrapolation of Efficacy and Safety in Paediatric Medicine Development, European Medicines Agency, Draft 31-Mar-2016, EMA/199678/2016. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/04/WC500204187.pdf (accessed 19 Sep, 2016).
101. Rostami-Hodjegan, A. ( 2012 ) Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology Clin. Pharmacol. Ther. 92, 50-61 10.1038/clpt.2012.65
102. Tsaioun, K., Blaauboer, B. J., and Hartung, T. ( 2016 ) Evidence-based absorption, distribution, metabolism, excretion and toxicity (ADMET) and the role of alternative methods ALTEX 33, 343-358 10.14573/altex.1610101
103. Zhao, P., Zhang, L., Grillo, J. A., Liu, Q., Bullock, J. M., Moon, Y. J., Song, P., Brar, S. S., Madabushi, R., Wu, T. C., Booth, B. P., Rahman, N. A., Reynolds, K. S., Gil Berglund, E., Lesko, L. J., and Huang, S. M. ( 2011 ) Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review Clin. Pharmacol. Ther. 89, 259-267 10.1038/clpt.2010.298
104. Salem, F., Rostami-Hodjegan, A., and Johnson, T. N. ( 2013 ) Do children have the same vulnerability to metabolic drug-drug interactions as adults? A critical analysis of the literature J. Clin. Pharmacol. 53, 559-566 10.1002/jcph.13
105. Rose, R. H., Neuhoff, S., Abduljalil, K., Chetty, M., Rostami-Hodjegan, A., and Jamei, M. ( 2014 ) Application of a physiologically based pharmacokinetic model to predict OATP1B1-related variability in pharmacodynamics of rosuvastatin CPT: Pharmacometrics Syst. Pharmacol. 3, e124 10.1038/psp.2014.24
106. Wiśniowska, B. and Polak, S. ( 2016 ) Virtual clinical trial toward polytherapy safety assessment: combination of physiologically based pharmacokinetic/pharmacodynamic-based modeling and simulation approach with drug-drug interactions involving terfenadine as an example J. Pharm. Sci. 105, 3415-3424 10.1016/j.xphs.2016.08.002
107. Scotcher, D., Jones, C., Posada, M., Galetin, A., and Rostami-Hodjegan, A. ( 2016 ) Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation AAPS J. 18, 1082-1094 10.1208/s12248-016-9959-1
108. Fisher, C. P., Plant, N. J., Moore, J. B., and Kierzek, A. M. ( 2013 ) QSSPN: dynamic simulation of molecular interaction networks describing gene regulation, signalling and whole-cell metabolism in human cells Bioinformatics 29, 3181-3190 10.1093/bioinformatics/btt552
109. ICH S7B ( 2005 ) The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by human Pharmaceuticals, ICH Finalised Guideline, May 2005. http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
110. ICH-E14 ( 2005 ) The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs, ICH Finalised Guideline, May 2005. http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html.
111. Mirams, G. R., Cui, Y., Sher, A., Fink, M., Cooper, J., Heath, B. M., Mcmahon, N. C., Gavaghan, D. J., and Noble, D. ( 2011 ) Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk Cardiovasc. Res. 91, 53-61 10.1093/cvr/cvr044
112. Kramer, J., Obejero-Paz, C., Myatt, G., Kuryshev, Y., Bruening-Wright, A., Verducci, J. S., and Brown, A. M. ( 2013 ) MICE models: superior to the HERG model in predicting Torsade de Pointes Sci. Rep. 3, 2100 10.1038/srep02100
113. Moreno, J. D., Yang, P.-C., Bankston, J. R., Grandi, E., Bers, Kass, R. S., and Clancy, C. E. ( 2013 ) Ranolazine for congenital and acquired late INa linked arrhythmias: in silico pharmacologic screening Circ. Res. 113, e50-61 10.1161/CIRCRESAHA.113.301971
114. Di Veroli, G. Y., Davies, M. R., Zhang, H., Abi-Gerges, N., and Boyett, M. R. ( 2013 ) High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment AJP Hear. Circ. Physiol. 304, H104-H117 10.1152/ajpheart.00511.2012
115. Di Veroli, G. Y., Davies, M. R., Zhang, H., Abi-Gerges, N., and Boyett, M. R. ( 2014 ) hERG Inhibitors With Similar Potency But Different Binding Kinetics Do Not Pose the Same Proarrhythmic Risk: Implications for Drug Safety Assessment J. Cardiovasc. Electrophysiol. 25, 197-207 10.1111/jce.12289
116. Moreno, J. D., Zhu, Z. I., Yang, P. C., Bankston, J. R., Jeng, M. T., Kang, C., Wang, L., Bayer, J. D., Christini, D. J., Trayanova, N. A., Ripplinger, C. M., Kass, R. S., and Clancy, C. E. ( 2011 ) A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms Sci. Transl. Med. 3, 98ra83 10.1126/scitranslmed.3002588
117. Mirams, G. R. and Noble, D. ( 2011 ) Is it time for in silico simulation of drug cardiac side effects? Ann. N. Y. Acad. Sci. 1245, 44-47 10.1111/j.1749-6632.2011.06324.x
118. Elkins, R. C., Davies, M. R., Brough, S. J., Gavaghan, D. J., Cui, Y., Abi-Gerges, N., and Mirams, G. R. ( 2013 ) Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment J. Pharmacol. Toxicol. Methods 68, 112-122 10.1016/j.vascn.2013.04.007
119. Noble, D., Garny, A., and Noble, P. J. ( 2012 ) How the Hodgkin - Huxley equations inspired the Cardiac Physiome Project J. Physiol. 590, 2613-2628 10.1113/jphysiol.2011.224238
120. Beattie, K. A., Luscombe, C., Williams, G., Munoz-Muriedas, J., Gavaghan, D. J., Cui, Y., and Mirams, G. R. ( 2013 ) Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge J. Pharmacol. Toxicol. Methods 68, 88-96 10.1016/j.vascn.2013.04.004
121. Davies, M. R., Mistry, H. B., Hussein, L., Pollard, C. E., Swinton, J., Valentin, J.-P., and Abi-Gerges, N. ( 2012 ) An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment Am. J. Physiol. Hear. Circ. Phys. 302, H1466-H1480 10.1152/ajpheart.00808.2011
122. Sager, P. T., Gintant, G., Turner, J. R., Pettit, S., and Stockbridge, N. ( 2014 ) Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium Am. Heart J. 167, 292-300 10.1016/j.ahj.2013.11.004
123. Fermini, B., Hancox, J. C., Abi-Gerges, N., Bridgland-Taylor, M., Chaudhary, K. W., Colatsky, T., Correll, K., Crumb, W., Damiano, B., Erdemli, G., Gintant, G., Imredy, J., Koerner, J., Kramer, J., Levesque, P., Li, Z., Lindqvist, A., Obejero-Paz, C. A., Rampe, D., Sawada, K., Strauss, D. G., and Vandenberg, J. I. ( 2016 ) A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm J. Biomol. Screening 21, 1-11 10.1177/1087057115594589
124. Jennings, P. ( 2015 ) The future of in vitro toxicology Toxicol. In Vitro 29, 1217-1221 10.1016/j.tiv.2014.08.011
125. Judson, R., Houck, K., Martin, M., Richard, A. M., Knudsen, T. B., Shah, I., Little, S., Wambaugh, J., Setzer, R. W., Kothiya, P., Phuong, J., Filer, D., Smith, D., Reif, D., Rotroff, D., Kleinstreuer, N., Sipes, N., Xia, M., Huang, R., Crofton, K., and Thomas, R. S. ( 2016 ) Analysis of the Effects of Cell Stress and Cytotoxicity on In Vitro Assay Activity Across a Diverse Chemical and Assay Space Toxicol. Sci. 153, 409-409 10.1093/toxsci/kfw148
126. Jennings, P., Limonciel, A., Felice, L., and Leonard, M. O. ( 2013 ) An overview of transcriptional regulation in response to toxicological insult Arch. Toxicol. 87, 49-72 10.1007/s00204-012-0919-y
127. Limonciel, A., Moenks, K., Stanzel, S., Truisi, G. L., Parmentier, C., Aschauer, L., Wilmes, A., Richert, L., Hewitt, P., Mueller, S. O., Lukas, A., Kopp-Schneider, A., Leonard, M. O., and Jennings, P. ( 2015 ) Transcriptomics hit the target: Monitoring of ligand-activated and stress response pathways for chemical testing Toxicol. In Vitro 30, 7-18 10.1016/j.tiv.2014.12.011
128. Peng, K. J., Wang, J. H., Su, W. T., Wang, X. C., Yang, F. T., and Nie, W. H. ( 2010 ) Characterization of two human lung adenocarcinoma cell lines by reciprocal chromosome painting Dongwuxue Yanjiu 31, 113-121 10.3724/SP.J.1141.2010.02113
129. Crean, D., Bellwon, P., Aschauer, L., Limonciel, A., Moenks, K., Hewitt, P., Schmidt, T., Herrgen, K., Dekant, W., Lukas, A., Bois, F., Wilmes, A., Jennings, P., and Leonard, M. O. ( 2015 ) Development of an in vitro renal epithelial disease state model for xenobiotic toxicity testing Toxicol. In Vitro 30, 128-137 10.1016/j.tiv.2014.11.015
130. Wilmes, A., Bielow, C., Ranninger, C., Bellwon, P., Aschauer, L., Limonciel, A., Chassaigne, H., Kristl, T., Aiche, S., Huber, C. G., Guillou, C., Hewitt, P., Leonard, M. O., Dekant, W., Bois, F., and Jennings, P. ( 2015 ) Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics Toxicol. In Vitro 30, 117-127 10.1016/j.tiv.2014.10.006
131. Wilmes, A., Limonciel, A., Aschauer, L., Moenks, K., Bielow, C., Leonard, M. O., Hamon, J., Carpi, D., Ruzek, S., Handler, A., Schmal, O., Herrgen, K., Bellwon, P., Burek, C., Truisi, G. L., Hewitt, P., Di Consiglio, E., Testai, E., Blaauboer, B. J., Guillou, C., Huber, C. G., Lukas, A., Pfaller, W., Mueller, S. O., Bois, F. Y., Dekant, W., and Jennings, P. ( 2013 ) Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress J. Proteomics 79, 180-194 10.1016/j.jprot.2012.11.022
132. Aschauer, L., Gruber, L. N., Pfaller, W., Limonciel, A., Athersuch, T. J., Cavill, R., Khan, A., Gstraunthaler, G., Grillari, J., Grillari, R., Hewitt, P., Leonard, M. O., Wilmes, A., and Jennings, P. ( 2013 ) Delineation of the key aspects in the regulation of epithelial monolayer formation Mol. Cell. Biol. 33, 2535-2550 10.1128/MCB.01435-12
133. Wieser, M., Stadler, G., Jennings, P., Streubel, B., Pfaller, W., Ambros, P., Riedl, C., Katinger, H., Grillari, J., and Grillari-Voglauer, R. ( 2008 ) hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics Am. J. Physiol. Renal Physiol. 295, F1365-1375 10.1152/ajprenal.90405.2008
134. Wilmes, A., Aschauer, L., Limonciel, A., Pfaller, W., and Jennings, P. ( 2014 ) Evidence for a role of claudin 2 as a proximal tubular stress responsive paracellular water channel Toxicol. Appl. Pharmacol. 279, 163-172 10.1016/j.taap.2014.05.013
135. Aschauer, L., Limonciel, A., Wilmes, A., Stanzel, S., Kopp-Schneider, A., Hewitt, P., Lukas, A., Leonard, M. O., Pfaller, W., and Jennings, P. ( 2015 ) Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: A transcriptomic study Toxicol. In Vitro 30, 106-116 10.1016/j.tiv.2014.10.005
136. Limonciel, A., Aschauer, L., Wilmes, A., Prajczer, S., Leonard, M. O., Pfaller, W., and Jennings, P. ( 2011 ) Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes Toxicol. In Vitro 25, 1855-1862 10.1016/j.tiv.2011.05.018
137. Jennings, P., Crean, D., Aschauer, L., Limonciel, A., Moenks, K., Kern, G., Hewitt, P., Lhotta, K., Lukas, A., Wilmes, A., and Leonard, M. O. ( 2015 ) Interleukin-19 as a translational indicator of renal injury Arch. Toxicol. 89, 101-106 10.1007/s00204-014-1237-3
138. Wilmes, A., Limonciel, A., Leonard, M., and Jennings, P. ( 2014 ) Translational Biomarkers, in Vitro and in Vivo, in In Vitro Toxicology Systems. Methods in Pharmacology and Toxicology (Bal-Price, A. and Jennings, P., Eds.) pp 459-478, Springer, New York.